Study shows gender gap in top medical journals

If the order of authors in medical studies didn’t matter, they might as well be arranged alphabetically, right? But the listing of first (and last) author does matter. Getting top billing can lead to increased prestige, pay and career opportunities.

A recent report from the British Medical Journal (BMJ) exposes a gender gap in the listing of authors in top tier medical research journals.

The study examined original research published in six highly respected journals between 1994 and 2014. The authors—Giovani Filardo, PhD, MPH, and Briget da Graca, MS, with Baylor Healthcare System in Dallas—found women to be more represented in 2014 than any prior year. But numbers have recently leveled off, suggesting women are underrepresented as lead authors.

The disparity exists despite women attending medical school in equal numbers as men in the U.S. since 2003.

In an accompanying editorial in BMJ, Kathryn M Rexrode, MD, MPH, argued eliminating this gender gap needs to be a priority for journals, universities and funding agencies.

NPR, along with Kaiser Health News, also investigated the study and the potential for gender bias in healthcare in its “All Things Considered” program.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.